Application of Box-Behnken Design to Optimize the Osmotic Drug Delivery System of Metoprolol Succinate and its In Vivo Evaluation in Beagle Dogs

被引:4
作者
Banerjee, Arti [1 ]
Verma, Priya Ranjan Prasad [2 ]
Gore, Subhash [1 ]
机构
[1] Mylan Labs Ltd, FDS, R&D Ctr, 31-34A Anrich Ind Estate, Hyderabad 502325, Telangana, India
[2] Birla Inst Technol, Ranchi, Bihar, India
关键词
Osmotic pump; Metoprolol succinate; Pore former; Box-Behnken design; Controlled drug delivery; CELLULOSE-ACETATE; EXTENDED-RELEASE; PUMP; FORMULATION; HYDROCHLORIDE; TABLETS; METHODOLOGY;
D O I
10.1007/s12247-016-9245-x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The objective of this study was to develop osmotic pump tablets of metoprolol succinate (MS) using water-soluble pore formers in the semipermeable membrane in place of orifice drilled on the membrane thereby abolishing the shortcomings associated with laser drilling technique. The formulation was optimized for coating variables such as semipermeable membrane level (X-1) and pore former level (X-2) by response surface methodology using Box-Behnken design (BBD) employing design expert software. The developed osmotic pump tablet was found to sustain the drug release up to 20 h at zero-order rate. The pharmacokinetic study in Beagle dogs showed delayed T-max and lower C-max compared to marketed brand TOPROL XL, indicating a slow and more sustained release behavior of MS from the optimized osmotic tablets in comparison with the existing matrix-based marketed dosage form. Thus, a novel approach for the controlled release of MS from osmotic pump tablets has been successfully developed using BBD, which is valuable for the advancement of controlled drug delivery of other water-soluble drugs.
引用
收藏
页码:120 / 133
页数:14
相关论文
共 52 条
  • [1] [Anonymous], 2014, The Atlas of Heart Disease and Stroke - Global Burden of Stroke
  • [2] [Anonymous], 2014, NEW J SCI, DOI DOI 10.1155/2014/756240
  • [3] [Anonymous], 2013, TURK J PHARM SCI
  • [4] [Anonymous], 2005, Guidance for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Health Volunteers
  • [5] [Anonymous], 2014, US PHARM 37 NAT FORM
  • [6] [Anonymous], 2003, Stability testing of New Drug Substances and Products
  • [7] USE OF MODIFIED ETHYLCELLULOSE LATTICES FOR MICROPOROUS COATING OF OSMOTIC TABLETS
    APPEL, LE
    ZENTNER, GM
    [J]. PHARMACEUTICAL RESEARCH, 1991, 8 (05) : 600 - 604
  • [8] Controlled Porosity Solubility Modulated Osmotic Pump Tablets of Gliclazide
    Banerjee, Arti
    Verma, P. R. P.
    Gore, Subhash
    [J]. AAPS PHARMSCITECH, 2015, 16 (03): : 554 - 568
  • [9] Barkas F, 2013, ANN GASTROENTEROL, V26, P23
  • [10] Optimisation of floating matrix tablets and evaluation of their gastric residence time
    Baumgartner, S
    Kristl, J
    Vrecer, F
    Vodopivec, P
    Zorko, B
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2000, 195 (1-2) : 125 - 135